Sign In
Buy IDXG
$1.75
-0.0100 (-0.568%)
At Close: Jun 03, 2026
Edited Transcript of IDXG earnings conference call or presentation 22-Apr-20 9:00pm GMT
07:48pm, Wednesday, 10'th Jun 2020
Q4 2019 Interpace Biosciences Inc Earnings Call
Strategies for improving Nigeria’s Healthcare practice proposed at the ISN Quality Assurance Summit - Businessday NG
04:15pm, Tuesday, 09'th Jun 2020
Medical laboratory professionals and quality assurance officers have been equipped with strategies necessary for the achievement of quality healthcare in Nigeria at the 5th edition of the ISN Quality
ISN Medical set to host 5th edition of its Quality Assurance Summit - Businessday NG
11:00am, Thursday, 04'th Jun 2020
ISN Medical, the leading supplier of medical diagnostics products and services, has scheduled the fifth edition of its quality assurance summit for Saturday, June 6, 2020. The quarterly event known as
The "Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis...
Molecular Diagnostics Market By Key Players, Deployment Type, Applications, Vertical, and Region – Forecast 2026
09:48am, Monday, 11'th May 2020
May 11, 2020 (AmericaNewsHour) --
Global Molecular Diagnostics Market is valued approximately at USD 8.4 billion in 2019 and is anticipated to grow with a...
ARK Genomic Revolution Multi-Sector ETF: An Overbought But Promising Niche Play
02:10pm, Friday, 08'th May 2020
I am neutral on ARKG, an exciting, niche biotech ETF that currently looks overbought on the charts. I expect investor interest in this space to stay elevated on
May 05, 2020 Xherald --
Veterinary Reference Laboratory (VRL) Market report will make detailed analysis mainly on in-depth research on the development...
Viking Therapeutics (VKTX) Received its Third Buy in a Row
11:32am, Saturday, 02'nd May 2020
After Stifel Nicolaus and H.C. Wainwright gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
04:56pm, Friday, 01'st May 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA), with a price target of $9.00. The company's shares
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
04:56pm, Friday, 01'st May 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA – Research Report),
Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
11:47am, Friday, 01'st May 2020
Maxim Group analyst Jason McCarthy maintained a Hold rating on Vertex Pharmaceuticals (VRTX) today. The company's shares closed last Thursday at $251.20.
